Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation activation in liver diseases.

B Kemkes-Matthes1, H Bleyl, K J Matthes

  • 1Zentrum für Innere Medizin, Universität Giessen, Germany.

Thrombosis Research
|October 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prehospital management of acute coronary syndrome in patients on long-term direct oral anticoagulant treatment].

Der Anaesthesist·2019
Same author

[Anticoagulation-direct oral anticoagulants].

Der Internist·2017
Same author

Hämostaseologie--Progress in Haemostasis. GTH is moving to a European scientific society.

Hamostaseologie·2016
Same author

Reduced platelet aggregation in a boy with scurvy.

Klinische Padiatrie·2012
Same author

[Hemorrhagic disorders].

Der Internist·2012
Same author

Inhibitor-immunology-study. Evaluation of inhibitor development in haemophilia B.

Hamostaseologie·2011

Liver disorders activate the coagulation cascade. While partial activation is common, complete activation leading to disseminated intravascular coagulation (DIC) only occurs in severe liver disease.

Area of Science:

  • Hepatology
  • Hematology
  • Coagulation Science

Background:

  • Liver disorders often involve coagulation system alterations due to reduced protein synthesis.
  • Controversy exists regarding enhanced intravascular consumption of coagulation factors in liver diseases.

Purpose of the Study:

  • To investigate whether coagulation activation in liver patients leads to a complete cascade activation (DIC) or a futile partial activation.
  • To differentiate coagulation patterns across various liver disease severities.

Main Methods:

  • Measurement of endogenous thrombin generation markers: Factor IXa-antithrombin (IXiAT) complexes.
  • Measurement of thrombin-antithrombin (TAT) complexes as indicators of thrombin activity.

Main Results:

Related Experiment Videos

  • Elevated IXiAT-complexes were observed in all examined liver diseases, indicating cascade activation.
  • Elevated TAT-complexes were predominantly found in severe conditions: chronic active hepatitis, decompensated cirrhosis, and end-stage liver disease.

Conclusions:

  • All examined liver diseases activate the coagulation cascade.
  • Complete coagulation cascade activation with DIC is restricted to patients with very severe liver disorders.